Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.
DURHAM, NC / ACCESSWIRE / January 8, 2021 / Heat Biologics, Inc. (“Heat”) (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, has announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually… Read More »Heat Biologics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
A report by The Insight Partner's on the Global Covid-19 Product Market discusses the growth of the market in great detail. It discusses thoroughly all factors promoting and deterring the market. The report also focuses on the competitive dynamics in
Covid-19 Product include range of products which are used for protection against covid-19. The range of products mainly include, face mask, sanitizers, disinfectant, personal protection equipment, hand gloves, oximeters and such other products. The covid-19 outbreak has drastically enhanced the
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEOS, ONCT, HTBX, FCEL, and CIDM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….